Navigation Links
Cardium Reports on Transdel Transaction
Date:7/28/2011

and effective; that Ketotransdel or other product candidates are seen as suitable or preferred products compared to other FDA-approved products that currently are or will be on the market; that our product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive; that our clinical study programs can be conducted and completed in an efficient and successful manner; that the FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; or that third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission.  Except as required by law, we undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2011 Cardium Therapeutics, Inc.  All rights reserved.

F
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cardium Announces Market Introduction of New Alena™ Clinical Strength Carb Blocker to Expand the MedPodium Healthy Lifestyle Product Line
2. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
3. Cardium Announces Cedars-Sinai Heart Institute as the SPECT Imaging Core Lab for the Recently Announced Generx® Phase 3 Clinical Registration Study in the Russian Federation
4. Cardium Presents First Quarter 2011 Financial Results and Reports on Near-Term Milestones
5. Cardium to Present at OneMedForum San Francisco 2011 Conference
6. Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process
7. Cardium Reports on Fourth Quarter and Year-End 2009 Financial Results and Recent Developments
8. Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development
9. Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds
10. Cardium Reports Non-Healing Wounds Continue to Challenge Patients and Healthcare Providers
11. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... N.J. , Sept. 1, 2015 Konica ... CS-7s Computed Radiography (CR) system, designed to deliver enterprise ... By utilizing the same Control Station as the Konica ... assured with an upgrade path from CR to DR. ... imaging to help improve workflow with unparalleled reliability and ...
(Date:9/1/2015)... UT Southwestern Medical Center President Dr. ... U.S. Representatives Michael C. Burgess , M.D., and ... the 21 st Century Cures Act, bipartisan legislation ... the United States Senate. ... Sciences members, department chairs, center directors, and leading researchers ...
(Date:9/1/2015)... 2015   Alpha Imaging LLC , a leading distributor of ... announced today that they have been awarded exclusive rights to represent ... Michigan.   The new territory supplements Alpha Imaging,s existing Shimadzu sales and ... Ohio , Indiana , Pennsylvania ... , West Virginia , Delaware ...
Breaking Medicine Technology:Konica Minolta Launches New CR System with Low-Cost Upgrade Path to DR 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5Alpha Imaging Expands Shimadzu Territory 2
... BEIJING, May 7, 2012 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. ... leading plasma-based biopharmaceutical companies in the People,s Republic of China, ... covering its first quarter 2012 results on May 9, 2012 ... p.m. in China on the same day. Hosting ...
... S. Weinstock and G. Scott Vezina of ... obtained a $78.5 million verdict on behalf of a child ... negligence. The child, now 3 years old, has severe spastic ... of an emergency cesarean section delivery. The case was tried, ...
Cached Medicine Technology:China Biologic Products to Host Earnings Conference Call on May 9, 2012 at 8:00 a.m. EDT (NY) 2$78.5 Million Jury Verdict In Philadelphia Birth Injury Case 2$78.5 Million Jury Verdict In Philadelphia Birth Injury Case 3
(Date:9/1/2015)... ... September 01, 2015 , ... Agriculture innovation, urban farming, local food access, ... to be discussed at Seedstock’s 4th Annual Sustainable Agriculture Conference : “Innovation and ... , In addition to keynotes Pierre Sleiman, founder and CEO of Go Green ...
(Date:9/1/2015)... ... 01, 2015 , ... METTLER TOLEDO has announced an upcoming ... requirements“ , featuring Ed Szczesny (Quality Assurance, Rhodes Pharmaceuticals) as guest presenter. This ... , Calibration, qualification, and the appropriate level of routine testing for laboratory ...
(Date:9/1/2015)... NY (PRWEB) , ... September 01, 2015 , ... ... as the 2015-2016 Distinguished Nurse Scholar-in Residence at the Institute of Medicine (IOM) ... Professor of Biomedical Informatics at Columbia University School of Nursing. A member of ...
(Date:9/1/2015)... ... September 01, 2015 , ... CanAm Enterprises LLC, (“CanAm”) is ... green cards (I-829 petition approval) from the USCIS through an investment in one ... of the EB-5 visa process for immigrant investors to become lawful permanent residents ...
(Date:9/1/2015)... MO (PRWEB) , ... September 01, 2015 , ... ... Wednesday, September 9, 2015 from 5:00 to 8:00 pm at the Marriott Indianapolis ... and groups with career opportunities will be attending from across the country. All ...
Breaking Medicine News(10 mins):Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 2Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 3Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 4Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 5Health News:Live Webinar from Pharmaceutical Technology and METTLER TOLEDO on Calibration and Qualification of Laboratory Instruments 2Health News:Columbia Nursing’s Suzanne Bakken Named Distinguished Institute of Medicine Nurse Scholar-in-Residence 2Health News:CanAm Enterprises Reaches Another Milestone with More Than 1,500 I-829 Petition Approvals 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 3Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 4
... to Request Additional Safety Study Prior to Approval, ... IDEV ) today announced that based on a recent ... the NDA filing for,NEBIDO(R), the Company expects the FDA ... prior to approving NEBIDO. The Company,currently believes that an ...
... Inc. (Nasdaq: MAPP ) today announced that ... Annual Global Healthcare,Conference on Tuesday, June 10, 2008, ... A live webcast of the presentation will be ... website at, http://www.mappharma.com . A replay will also ...
... are the leading causes of kidney,disease, which affects ... patients with high blood pressure and type 2 ... of kidney disease,which can reduce the risk of ... the US diagnosed with diabetes and high blood ...
... likely to continue abuse after college as well as ... (HealthDay News) -- College students with a "dense" family ... disorders, a U.S. study says. , While most university ... the time they,re young adults, some develop alcohol-use disorders, ...
... system also dictates weight gain, loss , , WEDNESDAY, June 4 ... may have a more direct role in whether you are ... A study on worms shows that serotonin levels in the ... acts independently to control eating and what your body does ...
... out in phases to purchase new 60,000 sq. ft ... ... threat: Hunger! In the effort to continue its vital mission of,feeding and educating ... million Growing Forward Campaign to find a new,home. After completing Phase I of ...
Cached Medicine News:Health News:Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status 2Health News:Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status 3Health News:Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status 4Health News:Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status 5Health News:MultiVu Video Feed: Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna(R) Reduces Key Marker of Kidney Disease 2Health News:MultiVu Video Feed: Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna(R) Reduces Key Marker of Kidney Disease 3Health News:Family History of Alcoholism Puts Student Drinkers at Risk 2Health News:Eating Habits Not Sole Cause of Thinness or Obesity 2Health News:Lowcountry Food Bank On the Way to $5 Million Goal with Over $2.5 Million Raised 2Health News:Lowcountry Food Bank On the Way to $5 Million Goal with Over $2.5 Million Raised 3Health News:Lowcountry Food Bank On the Way to $5 Million Goal with Over $2.5 Million Raised 4
Enzyme immunoassay for the quantitative determination of IgG autoantibodies against type IV collagen of glomerular or alveolar basement membrane (GBM) in serum and plasma....
... immunosorbent assay method for the semi-quantitative ... GBM in human serum. The results ... as an aid in the diagnosis ... of anti-GBM antibodies including Goodpastures Syndrome. ...
... intimately involved in the control of the ... tissues, which synthesize and secrete male and ... circulating FSH is controlled by these sex ... FSH Quantitative Test Kit is based ...
... Class II Direct to High Res SSP kits provide ... single tray. Locus specific typing on a single tray ... Straight from genomic DNA to high resolution results, ... level typing with a single tray , Unique reaction ...
Medicine Products: